Liquid Biopsy Market Size, Share, Growth, Trends & Forecast 2034

Market Overview:

According to IMARC Group's latest research publication, "Liquid Biopsy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034", The global liquid biopsy market size was valued at USD 2.60 Billion in 2025 and is projected to reach USD 7.61 Billion by 2034, exhibiting a CAGR of 12.31% during the forecast period 2026-2034.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How AI and Next-Generation Sequencing Are Transforming the Liquid Biopsy Market

• AI and machine learning are being integrated with liquid biopsy platforms to enhance data interpretation and clinical decision-making, enabling faster and more accurate identification of cancer-related biomarkers from blood samples.
• Continuous innovation in next-generation sequencing (NGS), digital PCR, and microfluidics is enhancing the sensitivity, specificity, and scalability of liquid biopsy assays across multiple cancer types and stages.
• According to WHO, there were an expected 20 million new cancer diagnoses globally and 9.7 million fatalities in a single year, with over 35 million additional cancer cases projected going forward, underscoring the urgency and scale of demand for non-invasive early detection tools.
• A University of Pennsylvania study published in Clinical Cancer Research demonstrated that a liquid biopsy test achieved 92% accuracy in diagnosing early pancreatic cancer, highlighting the clinical reliability of these solutions.
• Government and private investment in R&D activities is expanding the application of liquid biopsies beyond cancer diagnostics into prenatal screening, treatment monitoring, and residual disease detection, making it one of the most rapidly evolving segments in precision medicine.

Grab a sample PDF of this report: https://www.imarcgroup.com/liquid-biopsy-market/requestsample

Key Trends in the Liquid Biopsy Market

• Rising Prevalence of Cancer Driving Early Detection Demand: With cancer rates rising globally, clinicians and healthcare systems are increasingly adopting liquid biopsies as a non-invasive method to detect circulating tumor biomarkers such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes in bodily fluids like blood and urine. At the 2023 American Association of Cancer Research Annual Meeting, researchers presented findings on a liquid biopsy multicancer early detection test that analyzes DNA methylation using a novel platform, demonstrating the ability to detect 12 cancer types in a sample of around 4,000 participants without requiring the chemical treatment of DNA before sequencing.
• Surging Demand for Non-Invasive Prenatal Testing (NIPT): Traditional prenatal testing methods such as amniocentesis carry a 0.13% chance of singleton loss and an estimated overall risk of 1 in 100. Liquid biopsy-based NIPT, which analyzes cell-free fetal DNA circulating in the mother's blood, offers a safer alternative with high accuracy in detecting chromosomal abnormalities including trisomy 21, trisomy 18, and trisomy 13 from as early as nine to ten weeks of pregnancy. In November 2023, Yourgene Health, a subsidiary of Novacyt, collaborated with Laboriad to introduce the first NIPT platform in Morocco, expanding access to non-invasive prenatal screening in underserved markets.
• Expanding R&D Activities and Clinical Trial Investment: Rising technological advancements in liquid biopsy are escalating the frequency of cancer screening, drug trial optimization, and therapeutic selection. In June 2023, Anzu Partners led a USD 15 Million Series A investment round for Codetta Biosciences, with contributions from Genoa Ventures and VC23 LLC, to accelerate the development of its multi-omic dsPCR platform for liquid biopsy applications. In April 2024, NewBiologix SA launched its next-generation sequencing and optical mapping platform to provide comprehensive genomic analysis services to the biopharmaceutical industry.
• Shift Towards Multi-Analyte and Personalized Medicine Approaches: The liquid biopsy market is witnessing a pronounced shift toward multi-analyte testing, with platforms designed to simultaneously analyze CTCs, cfDNA, and extracellular vesicles. This approach supports personalized treatment selection by offering a more complete picture of tumor biology, treatment response, and disease progression in real time.
• Integration of Digital Health Technologies: The convergence of liquid biopsy with artificial intelligence, cloud-based bioinformatics, and digital health platforms is creating new opportunities to improve diagnostic accuracy, streamline clinical workflows, and enable scalable population-level cancer screening programs.

Growth Factors in the Liquid Biopsy Market

• Increasing Cancer Incidence Globally: The rising prevalence of cancer owing to changing lifestyle patterns, particularly among working professionals, is one of the primary drivers of demand for non-invasive diagnostic solutions. Liquid biopsies enable early detection of cancer at stages when tumors are more amenable to curative treatment, directly improving patient outcomes and reducing the burden on healthcare systems.
• Technological Advancements in Diagnostic Platforms: Continuous improvements in sequencing technologies, microfluidics, and bioinformatics are enhancing the performance and commercial viability of liquid biopsy assays. In September 2023, Pillar Biosciences launched oncoReveal Core LBx, a research-use-only NGS kit designed to enable laboratories with a pan-cancer liquid biopsy-based tumor profiling solution, reflecting the pace of product innovation across the industry.
• Growing Clinical Utility Across Cancer Types: Liquid biopsy's ability to detect and monitor a broad spectrum of cancers including lung, breast, colorectal, prostate, and liver cancer is expanding its adoption across hospitals, laboratories, and clinical research centers. In April 2024, researchers at The Royal Marsden and Guardant Health collaborated to develop Marsden360, a cutting-edge circulating tumor DNA test designed to accelerate and personalize treatment for thousands of lung cancer patients.
• Rising Adoption in Hospitals and Laboratories: As the clinical utility of liquid biopsy in cancer management becomes increasingly recognized, hospitals and diagnostic laboratories are scaling their adoption of these tests. In May 2024, Syndicate Bio, a Nigeria-based biotechnology laboratory, collaborated with SophiaGenetics to provide comprehensive genomic profiling and liquid biopsy services, reflecting growing global demand beyond established markets.
• Strategic Acquisitions Strengthening Market Positions: Key players are actively pursuing acquisitions to expand their liquid biopsy portfolios and capabilities. In April 2023, Quest Diagnostics acquired Haystack Oncology, an early-stage oncology company focused on minimal residual disease detection, the fastest-growing category of liquid biopsy testing, to enhance its ability to detect residual or recurring cancer and better inform therapy decisions.

Ask analyst of customized report: https://www.imarcgroup.com/request?type=report&id=5125&flag=E

Leading Companies Operating in the Global Liquid Biopsy Industry:

• ANGLE plc
• Bio-Rad Laboratories Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Guardant Health Inc.
• Illumina Inc.
• Lucence Health Inc.
• Menarini Silicon Biosystems
• Personalis, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

Liquid Biopsy Market Report Segmentation:

Breakup By Product and Service:

• Kits and Reagents
• Platforms and Instruments
• Services

Kits and reagents account for the largest segment on account of the surging demand for liquid biopsy tests, especially for cancer diagnostics, along with rising R&D activities by key players focused on developing advanced isolation and purification kits for cell-free DNA from plasma or serum samples.

Breakup By Circulating Biomarker:

• Circulating Tumor Cells
• Extracellular Vesicles
• Circulating Tumor DNA
• Others

Circulating tumor cells hold the largest share in the market owing to their wide range of applications in biomarkers such as gene expressions, protein expressions, and DNA mutations, and their growing clinical utility in cancer diagnosis, prognosis, and treatment monitoring across multiple cancer types.

Breakup By Cancer Type:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Others

Lung cancer accounts for the majority of the market share due to the strong clinical suitability of liquid biopsy for non-invasive detection and real-time longitudinal monitoring of lung tumors, enabling timely adjustments in treatment strategies and facilitating earlier detection when interventions are most effective.

Breakup By End User:

• Hospitals and Laboratories
• Academic and Research Centers
• Others

Hospitals and laboratories hold the largest share in the market owing to the growing adoption of liquid biopsy tests for cancer diagnosis and treatment monitoring, driven by the recognized clinical utility of these non-invasive methods for delivering actionable diagnostic, prognostic, and therapeutic insights.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America exhibits a clear dominance in the market owing to high cancer incidence rates, continual technological advancements in NGS and digital PCR, extensive R&D activities conducted by key players, and ongoing improvements across the healthcare industry that are driving widespread adoption of liquid biopsy solutions.

Recent News and Developments in the Liquid Biopsy Market

• May 2024: VESICA HEALTH, INC., a leading multi-omics liquid biopsy company, launched its laboratory developed AssureMDx test to improve the management of hematuria patients and support the early detection of bladder cancer.
• April 2024: City of Hope, one of the largest cancer research and treatment organizations in the United States, collaborated with DELFI Diagnostics, Inc. to utilize DELFI's FirstLook Lung, a blood-based lung cancer liquid biopsy screening test, aimed at improving screening rates in underserved communities in Los Angeles County.
• April 2024: SOPHiA GENETICS announced that Nigeria-based Syndicate Bio signed on to adopt MSK-ACCESS powered by SOPHiA DDM, expanding access to advanced liquid biopsy and genomic profiling services in emerging markets.
• April 2024: Researchers at The Royal Marsden and Guardant Health collaborated to develop Marsden360, a cutting-edge circulating tumor DNA test designed to accelerate and personalize treatment for thousands of lung cancer patients.
• June 2023: Anzu Partners led a USD 15 Million Series A investment round for Codetta Biosciences to accelerate development of its multi-omic dsPCR platform for liquid biopsy, with contributions from Genoa Ventures and VC23 LLC.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201-971-6302